Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.31 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24298126 | 0.93 | SYK (0.32) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24323223 | 0.93 | SYK (0.32) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24324763 | 0.92 | NPC1 (0.31) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24299042 | 0.92 | NPC1 (0.31) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24298904 | 0.90 | LOXL2 (0.31) | — | |
| SCHEMBL24324181 | 0.88 | SYK (0.31) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24298181 | 0.87 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24298196 | 0.87 | MEN1 (0.30) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL24298810 | 0.87 | AAK1 (0.34) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL22509294 | 0.87 | AAK1 (0.34) | MEN1NPC1ALDH1A1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |